Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis

详细信息    查看全文

• 作者：Martin J. Bergman ; Eric P. Elkin ; Sarika Ogale ; Tripthi Kamath…
• 关键词：Anti ; rheumatic agents ; Arthritis ; rheumatoid ; Biological therapy ; Treatment failure ; Tumor necrosis factor alpha
• 刊名：Rheumatology and Therapy
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：1
• 期：1
• 页码：21-30
• 全文大小：388KB
• 参考文献：1.American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328鈥?6.
  2.Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.PubMed Central PubMed CrossRef
  3.Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51:v22鈥?0.CrossRef
  4.Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment Of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35:2136鈥?7.PubMed CrossRef
  5.Pincus T, Bergman MJ, Yazici Y. RAPID3鈥攁n index of physical function, pain, and global status as 鈥渧ital signs鈥?to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis. 2009;67:211鈥?5.PubMed
  6.Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine Assessment Of Patient Index Data) severity categories and response criteria: similar results to DAS28 and CDAI in the RAPID1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol (CZP). Arthritis Care Res. 2011;63:1142鈥?.CrossRef
  7.Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine. 2006;73:718鈥?4.PubMed CrossRef
  8.Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96鈥?03.PubMed
  9.Gomez-Reino JJ, Carmona L, for the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther (2006);8:R29.
  10.Navarro-Sarabia F, Ruiz-Montesinos D, Hernandez B, et al. DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMC Musculoskelet Disord. 2009;10:91.PubMed Central PubMed CrossRef
  11.Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007;46:1191鈥?.PubMed CrossRef
  12.Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the south Swedish arthritis treatment group register. Rheumatology. 2008;47:507鈥?3.PubMed CrossRef
  13.Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF伪 blocker failure. Biologics. 2012;6:191鈥?.PubMed Central PubMed
  14.Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417鈥?3.
  15.Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of rheumatoid arthritis patients benefit most from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents? Ann Rheum Dis. 2008;67:127. Abstract.
  16.Venkatachalam S, Roskell S, Suchitra R, Price T, Mulherin D, Sheeran T. Rituximab may be more effective than switching to an alternative TNF inhibitor in rheumatoid arthritis patients who have failed other TNF inhibitors. Rheumatology 2008;47:ii31. Abstract.
  17.Kim HL, Lee MY, Park SY, et al. Comparative effectiveness of cycling of tumor necrosis factor-伪 (TNF-伪) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-伪 inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37:662鈥?0.PubMed CrossRef
  18.Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71:1861鈥?.PubMed CrossRef
  19.Wakabayashi H, Hasegawa M, Nishioka Y, Sudo A, Nishioka K. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? a retrospective study. Mod Rheumatol. 2012;22:116鈥?1.PubMed CrossRef
  
• 作者单位：Martin J. Bergman (1)
  Eric P. Elkin (2)
  Sarika Ogale (3)
  Tripthi Kamath (3)
  Max I. Hamburger (4)
  
  1. Taylor Hospital, 175 East Chester Pike, Ridley Park, PA, 19078, USA
  2. ICON Clinical Research, 456 Montgomery Street, Suite 2200, San Francisco, CA, 94104, USA
  3. Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
  4. Rheumatology Associates of Long Island, 1895 Walt Whitman Road, Melville, NY, 11747, USA
  
• 刊物类别：Rheumatology; Orthopedics; General Practice / Family Medicine; Internal Medicine; Quality of Life Re
• 刊物主题：Rheumatology; Orthopedics; General Practice / Family Medicine; Internal Medicine; Quality of Life Research;
• 出版者：Springer Healthcare
• ISSN：2198-6584

文摘

Introduction The aim of this study was to compare the response between subsequent use of anti-tumor necrosis factor 伪 (anti-TNF) agents and biologic disease-modifying anti-rheumatic drugs (bDMARD) with other mechanism of action (MOA) in rheumatoid arthritis (RA) patients with history of anti-TNF treatment as their first bDMARD.